Contributed by Florida Healthcare Law Firm, Key Vendor
What changed?
Indiana Senate Enrolled Act 282, enacted as Public Law 136, creates new requirements for medical spas and for certain drug-compounding activities. The new statutory chapters became effective July 1, 2026. Medical spa registration becomes mandatory on January 1, 2027, and the Medical Licensing Board of Indiana must establish the registration procedure by October 1, 2026.
SEA 282 does not expressly declare all mobile IV services illegal. It does, however, impose a significant location restriction on businesses that meet Indiana’s new definition of a “medical spa.” Because the definition expressly includes wellness and addresses parenteral nutrient therapies, many traditional mobile IV models may be affected.
Does the law apply to a mobile IV provider?
A facility or practice is a medical spa under SEA 282 when it satisfies three elements:
1. It offers or provides medical health care services
2. it prepares, administers, or dispenses prescription drugs, or otherwise uses prescription drugs for intravenous, intramuscular, or subcutaneous delivery; and
3. it holds itself out as focused on cosmetic or lifestyle treatments.
The statute separately identifies weight loss, wellness, and longevity. It also includes certain cosmetic or aesthetic services involving prescription drugs for weight loss, botulinum toxin and dermal fillers, hair loss, hormone therapies, or parenteral nutrient therapies, as well as certain cosmetic laser and energy-device services. Whether a particular mobile IV provider is covered therefore depends on its actual services, prescription-drug activities, routes of administration, marketing, operational structure, and any applicable exclusion.
What is the mobile-services restriction?
SEA 282 states that a medical spa may not provide health care services and cosmetic and lifestyle treatments at a location other than the medical spa office, except when the service or treatment is performed elsewhere for educational or training purposes.
The act does not define “medical spa office” and does not expressly create exceptions for patient homes, hotels, workplaces, event venues, fitness facilities, or mobile vehicles.
Accordingly, if a mobile IV business meets the definition of a medical spa, providing covered services away from its medical spa office appears to be restricted. This provision took effect July 1, 2026 and was not expressly deferred until the registration requirement begins. Its precise application to mobile units, hybrid practices, and other operating models may require additional guidance from Indiana regulators.
Are any practices excluded?
The medical spa definition excludes a physician’s office and a facility or practice that is otherwise licensed by Indiana.
SEA 282 does not define those exclusions. It does not explain whether physician ownership, medical direction, a collaborative agreement, use of a physician’s address, or another professional license is sufficient.
Providers should not assume that a nominal physician relationship automatically creates an exclusion. The analysis should consider the actual ownership, location, clinical control, staffing, licensure, and operations of the practice.
What begins in 2027?
Beginning January 1, 2027, a medical spa must be registered with the Medical Licensing Board before doing business in Indiana.
The application must disclose the medical spa’s names, address, website, intended services, responsible practitioner, applicable collaborating or supervising practitioner, and whether the spa engages in or plans to engage in compounding at the medical spa. Operating an unregistered medical spa may result in a fine of up to $5,000 and an order to obtain registration.
A registered medical spa must designate a responsible practitioner with prescriptive authority and appropriate education and training. The responsible practitioner must be physically present at the medical spa location for sufficient time to carry out the practitioner’s compliance responsibilities and must confirm that personnel are properly licensed, acting within their scopes of practice, and appropriately trained.
What does SEA 282 say about compounding?
SEA 282 defines compounding to include combining, admixing, mixing, diluting, pooling, reconstituting, or otherwise altering a drug or bulk drug substance to create a compounded drug.
Under the statutory definition, those activities are performed by an Indiana-licensed pharmacist or physician, or by an individual under the supervision of the pharmacist or physician. The definition does not independently expand any professional’s scope of practice and does not separately identify an advanced practice registered nurse or physician assistant as a compounding supervisor.
The definition excludes mixing or reconstitution performed according to FDA-approved manufacturer labeling and other manufacturer directions consistent with that labeling. A standing order or internal protocol does not, by itself, establish that this exception applies.
These compounding provisions are not limited to registered medical spas. Mobile IV providers should identify every step in which a drug or ingredient is mixed, diluted, reconstituted, added to an IV bag, or otherwise altered and determine who performs and supervises that activity.
What about bulk drug substances?
When compounding involves a bulk drug substance, SEA 282 imposes sourcing and quality requirements. Among other things, the substance generally may not be veterinary grade or research grade, must be manufactured by an FDA-registered human drug establishment, must be accompanied by a certificate of analysis containing specified information, and must undergo quality-control testing. The compounding must also comply with federal law and applicable United States Pharmacopeia chapters.
The definition expressly includes amino acids. Vitamins, minerals, herbs, essential oils, extracts, and other nonpharmaceutical ingredients are excluded only when they do not otherwise meet the statute’s pharmacological-purpose definition.
Are adverse events reportable?
A medical spa must notify the Medical Licensing Board within 15 days after a qualifying serious adverse event. The definition includes certain occurrences requiring medical or surgical intervention, death, a life-threatening occurrence, inpatient hospitalization, or prolongation of an existing hospitalization.
The reporting provision was effective July 1, 2026 and is not expressly limited to registered medical spas. However, reports must be submitted in the manner prescribed by the Board, so providers should monitor the Board’s implementation of the reporting process.
What should providers do now?
Indiana mobile IV providers should promptly determine whether their operations meet the medical spa definition and identify all services performed away from a fixed clinical office. Providers relying on the physician-office or licensed-practice exclusion should confirm that the actual structure supports that position.
Providers should also review medication sourcing, storage, transportation, labeling, preparation, administration, and disposal. Particular attention should be given to any activity involving the mixing, dilution, reconstitution, or addition of ingredients in a vehicle, home, hotel, workplace, or other off-site setting.
Finally, providers that may qualify as medical spas should prepare for registration and monitor guidance from the Medical Licensing Board, Indiana Board of Pharmacy, and applicable professional licensing boards.
Bottom line
SEA 282 does not categorically prohibit every mobile IV service in Indiana. It does create an immediate and substantial location restriction for a provider that meets Indiana’s definition of a medical spa. Because the definition includes wellness and addresses parenteral nutrient therapies, many traditional mobile IV models may be implicated.
The application of the law to a particular provider will depend on its services, medication practices, marketing, professional structure, location, and any applicable statutory exclusion.
This alert is provided for general educational purposes and does not constitute legal advice regarding any particular provider, license, medication, service, or business model.